• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Dyadic International Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    6/2/25 4:50:35 PM ET
    $DYAI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $DYAI alert in real time by email
    dyai20250602_8k.htm
    false 0001213809 0001213809 2025-05-29 2025-05-29
    --12-31
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    FORM 8-K
     

     
    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
    Date of Report (date of earliest event reported): May 29, 2025
     

     
    Dyadic International, Inc.
    (Exact name of registrant as specified in its charter)
     

     
     
    Delaware 000-55264 45-0486747
    (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number)
     
    1044 North U.S. Highway One, Suite 201
    Jupiter, FL 33477
    (Address of principal executive offices and zip code)
     
    (561) 743-8333
    (Registrant’s telephone number, including area code)
     
    N/A
    (Former Name or Former Address, if Changed Since Last Report)
     
    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
     
     
    Securities registered pursuant to Section 12(b) of the Act
     
    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, par value $0.001 per share
    DYAI
    The Nasdaq Stock Market LLC
     
    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     
     

     
     
    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
     
    On May 29, 2025, the board of directors (the “Board”) of Dyadic International, Inc. (the “Company”) appointed Joseph Hazelton as President of the Company. Mr. Hazelton, who joined the Company in 2021, will also continue to serve as its Chief Operating Officer, and Mark A. Emalfarb will continue to serve as Chief Executive Officer and as a member of the Board.
     
    Mr. Hazelton’s biography is included in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025. Mr. Hazelton has no family relationship with any of the Company’s directors or executive officers, and no direct or indirect material interest in any related person transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There are no arrangements or understandings between Mr. Hazelton and any other person pursuant to which he was appointed as President of the Company.
     
    In connection with Mr. Hazelton’s promotion, the Board approved an increase to his 2025 base salary of approximately 10% to $320,000, and a stock option grant for 2025 of 25,000 shares, which have a ten-year term, subject to earlier expiration upon termination, and vest annually in equal installments over four years on each anniversary of the grant date, subject to continued service on each vesting date. No other changes were made to Mr. Hazelton’s existing employment agreement, which provides for an annual bonus of up to 30% of his base salary, and an annual stock option award made at the discretion of the Board based on Mr. Hazelton’s performance.
     
    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
     
    On May 29, 2025, the Board amended and restated the Company’s Third Amended and Restated Bylaws (as amended and restated, the “Bylaws”), effective immediately. Among other things, the amendments relate to (i) clarifying the role of the inspectors of election at stockholder meetings pursuant to the Delaware General Corporation Law, (ii) clarifying the procedures for virtual meetings of stockholders, (iii) clarifying and modernizing the provisions around the list of stockholders made available before stockholder meetings, (iv) updating and streamlining the provisions related to the officers of the corporation, (v) updating and streamlining the provisions related to meetings of board committees and (vi) making certain other immaterial clarifying and/or conforming changes.
     
    The foregoing summary of the Bylaws does not purport to be a complete description and is qualified in its entirety by reference to the full text of the Bylaws, a copy of which is attached hereto as Exhibit 3.1 and incorporated herein by reference. Additionally, a copy of the Bylaws that is marked to show changes to the original bylaws (additions are underlined and deletions are struck through), is also attached hereto as Exhibit 3.2 and incorporated herein by reference.
     
    Item 7.01. Regulation FD Disclosure.
     
    On June 2, 2025, the Company issued a press release regarding the appointment of Mr. Hazelton as President. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
     
    The information in Item 7.01 of this Current Report on Form 8-K, including the information set forth in Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. Such information shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
     
    Item 9.01. Financial Statements and Exhibits.
     
    (d) Exhibits
     
     
    Exhibit
    Number
    Description
         
      3.1 Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025.
      3.2 Fourth Amended and Restated Bylaws of Dyadic International, Inc., effective May 29, 2025 (marked).
      99.1 Press Release dated June 2, 2025.
      104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
     
     

     
     
    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
    Date: June 2, 2025
     
    Dyadic International, Inc.
    By:
    /s/ Ping Rawson
    Name: 
    Ping Rawson
    Title: 
    Chief Financial Officer
     
     
    Get the next $DYAI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DYAI

    DatePrice TargetRatingAnalyst
    7/18/2022Buy → Neutral
    Dawson James
    12/17/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $DYAI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Dyadic International downgraded by Dawson James

      Dawson James downgraded Dyadic International from Buy to Neutral

      7/18/22 9:59:51 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. initiated coverage on Dyadic International with a new price target

      HC Wainwright & Co. initiated coverage of Dyadic International with a rating of Buy and set a new price target of $7.00

      12/17/21 6:17:22 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Financials

    Live finance-specific insights

    See more
    • Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

      5/14/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports 2024 Year-End Financial Results and Business Updates

      Strong revenue performance, including approximately $1.9 million milestone and license revenue recognized in 2024Up to $7.5 million in grants awarded from CEPI and Gates Foundation intended to accelerate the C1 platform development timeline to manufacture vaccines and antibodies faster at a lower costGrowth in commercial pipelines with multiple products nearing market launch, including Human Serum Albumin and DNASe1Expanded alternative protein portfolio with six additional life science products in development for research, nutritional, and cell culture media applicationsContinued advancements in animal and human healthCash and investment-grade securities of $9.3 million as of December 31, 20

      3/26/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by President and COO Hazelton Joseph P

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      6/6/25 11:16:59 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Kaye Jack exercised 30,000 shares at a strike of $1.33 and covered exercise/tax liability with 27,517 shares, increasing direct ownership by 4% to 59,649 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      3/7/25 4:07:16 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Herbst Seth exercised 25,000 shares at a strike of $0.97, increasing direct ownership by 16% to 180,759 units (SEC Form 4)

      4 - DYADIC INTERNATIONAL INC (0001213809) (Issuer)

      1/8/25 5:19:28 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/13/24 4:41:59 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      2/1/24 4:15:18 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Dyadic International Inc. (Amendment)

      SC 13G/A - DYADIC INTERNATIONAL INC (0001213809) (Subject)

      3/14/23 4:01:06 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    SEC Filings

    See more
    • Dyadic International Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      6/2/25 4:50:35 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic International Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      5/14/25 4:31:48 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Dyadic International Inc.

      10-Q - DYADIC INTERNATIONAL INC (0001213809) (Filer)

      5/14/25 4:31:21 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications

      Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutri

      6/2/25 8:35:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress

      Expanded life science and industrial portfolio with six additional life science products in developmentAdvances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme marketsUp to $4.5 million research grant awarded from the Coalition for Epidemic Preparedness (CEPI)Launched research for $3.0 million Gates Foundation grant for malaria and RSV antibody programsSelected to participate in the inaugural meeting of the "European Vaccines Hub for Pandemic Readiness (EVH)" project.Scientific Pre-Publication – "Expression and Characterization of SARS-CoV-2 Spike Protein in Thermothelomyces heterothallica C1"Cash, cash equivalents and invest

      5/14/25 4:05:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

      JUPITER, Fla., May 01, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as non-pharmaceutical applications including food, non-food and industrial applications, today announced that it will report its financial results for the first quarter 2025 and host a corporate update conference call on Wednesday, May 14, 2025. Conference Call Information Date: Wednesday, May 14, 2025 Time: 5:00 p.m. Eastern Time Dial-in numbers: Toll Free: +1-877-407-0784; International +1-201-689-8560

      5/1/25 3:00:00 PM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $DYAI
    Leadership Updates

    Live Leadership Updates

    See more
    • Dyadic Appoints Doug Pace to Its Executive Leadership Team

      JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and

      10/9/23 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dyadic Appoints Chief Business Officer to Executive Leadership Team

      JUPITER, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products today announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately. The creation of this role supports the global commercialization of the Company's new and existing business initiatives, including corporate strategy, business and corporate develo

      11/9/21 8:30:00 AM ET
      $DYAI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care